Sechenov School
Home › Pharmacology › Anti-influenza Drugs

Anti-influenza Drugs

Therapia antiviralis contra grippum

For medical students2 min readUpdated 2026-10-10

The study of anti-influenza drugs is based on understanding the structure of the influenza virus and its replication stages in the host organism. The interaction of viral structures with the host cell determines the key pharmacological targets.

Virus TypesOrthomyxoviruses are divided into types A, B, and C; type A is the most contagious.
M2 ProteinForms an ion channel in the viral envelope, facilitating acidification and uncoating of the virion.
RimantadineBlocks M2 ion channels, disrupting proton transport and preventing deproteinization (uncoating).
NeuraminidaseAn enzyme that cleaves the bonds between the virus and sialic acids to allow viral release from the cell.
OseltamivirInhibits neuraminidase, preventing the release of new virions and the spread of infection.

Influenza Virus Structure and Surface Proteins

Influenza viruses belong to the Orthomyxoviridae family and contain single-stranded, segmented RNA. The internal structure consists of a ribonucleoprotein surrounded by matrix protein M1. The outer lipid envelope (supercapsid) contains surface glycoproteins that determine the virus subtype and act as antigens.

Key surface structures include:

Adsorption, Penetration, and the Role of the M2 Protein

The infectious process begins with the virus attaching to the target cell via the interaction of hemagglutinin with sialic acids. The virion then enters the cell via endocytosis, forming an endosome.

Inside the endosome, the environment becomes acidified. Hydrogen ions enter the viral particle through the proton channel formed by the M2 protein. This process leads to the dissociation of the matrix protein and ribonucleoproteins—deproteinization occurs, releasing viral RNA into the cytoplasm.

The pharmacological agent rimantadine selectively blocks M2 ion channels, preventing endosomal acidification and viral uncoating.

Intracellular Synthesis, Assembly, and Release of Virions

The released viral RNA is transported into the host cell nucleus, where viral RNA polymerase mediates genome replication and viral mRNA transcription. The resulting mRNA enters the cytoplasm, where host ribosomes synthesize the required proteins.

New virions assemble at the cell membrane, after which the viral particles bud off. In the final stage, hemagglutinin retains new virions on the surface of the infected cell.

The enzyme neuraminidase cleaves this bond, ensuring the final separation of viral particles. The drug oseltamivir inhibits neuraminidase, blocking the spread of the infection.

Mnemonic

M2 — Military 2-way gate (blocked by rimantadine); Neuraminidase — Nimble shears (snip the bond from the cell, blocked by oseltamivir).

Frequently asked questions

What is the function of the M2 protein in the influenza virus?

The M2 protein forms a specific ion channel in the viral envelope. Through this channel, hydrogen ions enter the virion during endosome acidification, triggering the uncoating process.

Which drug blocks M2 ion channels and what is its effect?

Rimantadine blocks the function of M2 ion channels. This disrupts proton transport into the virion and prevents its uncoating.

What is the role of neuraminidase in the viral life cycle?

Neuraminidase cleaves the bond between hemagglutinin and sialic acids on the cell membrane. This ensures the detachment of new virions from the infected cell and their release to infect other cells.

Where do influenza virus replication and transcription take place?

Viral genome replication and mRNA transcription take place in the nucleus of the host cell.

Go deeper

More topics in Pharmacology

Microbial Drug ResistanceNadololOther Parenteral and Topical Routes of AdministrationAdsorbent AgentsClassification of Antiepileptic DrugsPrasugrelInterferon Drugs: Classification, Mechanism and Clinical UseArachidonic Acid MetabolismMechanism of Action of HormonesChloroquineEnalaprilOmalizumabPharmacology →